The Randomized OPTIMAL-ACT Trial

NCT03772613 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease
Ischemic Heart Disease
Anticoagulant-induced Bleeding
Coronary Syndrome

Interventions

DRUG: Unfractionated heparin

Sponsor

Mayo Clinic